JCRB4037 KMS21R
Cell information
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB4037 | Cell Name | KMS21R |
|---|---|---|---|
| Profile | Lenalidomide-resistant human myeloma cell line established by long-term exposure of KMS21 cells to low concentration lenalidomide for about one year. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 62-year-old |
| Identity | available | Tissue for Primary Cancer | hemo-lymphocytic |
| Case history | hyperammonaemia | Metastasis | Y |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | lymphocyte-like | Character | |
| Classify | tumor | Established by | Takemi OTSUKI & Yutaka HATTORI |
| Registered by | Yutaka HATTORI | Regulation for Distribution | |
| Comment | Year | ||
| Medium | RPMI1640 medium with 10% fetal bovine serum. | Methods for Passages | Subculture twice a week by dilution. |
| Cell Number on Passage | Race | Japanese | |
| CO2 Conc. | 5% | Tissue Sampling | bone marrow |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:34979567 | SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma. Yamamoto T,Nakayama J,Yamamoto Y,Kuroda M,Hattori Y,Ochiya T Blood Adv. 2022 Apr 26;6(8):2480-2495 |
| Pubmed id:35194739 | Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells. Hattori Y,Futo T,Uozaki R,Ichikawa D,Yamaguchi T,Yamamoto T,Matsushita M,Hirao M Int J Hematol. 2022 Apr;115(4):605-608 |
| Images |
|---|
      |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB4037 | Cell Name | KMS21R |
|---|---|---|---|
| LOT No. | 08292024 | Lot Specification | distribution |
| Medium | RPMI1640 medium (GIBCO) with 10% heat inactivated fetal bovine serum (Nichirei Cat. # 174112, Lot 20M00K) and Lenalidomide 0.1uM (1000x dilution:0.1mM stock DMSO solution) | Temperature | 37 C |
| Cell Density at Seeding | 0.876-2.65x10^5 cells/ml | Methods for Passages | dilution |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.73x10^6 |
| Viability at cell freezing (%) | 84.19 | Antibiotics Used | NT |
| Passage Number | p17 | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:10,11 D13S317:8,14 D7S820:8,13 D16S539:9 VWA:18 TH01:7,9 AM:X TPOX:8 CSF1PO:12,13 |
| Adhesion | Exoteric Gene | NT | |
| Medium for Freezing | BAMBANKER (LYMPHOTEC Inc., CS-02-001, NIPPON Genetics Co., LTD) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 70.76 | Additional information |
| Images |
|---|
|
|